This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Practice Guideline

. 2011 Mar;53(3):1020-2.

doi: 10.1002/hep.24199.

Management of hepatocellular carcinoma: an update

Jordi Bruix¹, Morris Sherman; American Association for the Study of Liver Diseases

Affiliations

PMID: 21374666
PMCID: PMC3084991
DOI: 10.1002/hep.24199

Free PMC article

Practice Guideline

Management of hepatocellular carcinoma: an update

Jordi Bruix et al. Hepatology. 2011 Mar.

Free PMC article

. 2011 Mar;53(3):1020-2.

doi: 10.1002/hep.24199.

Authors

Jordi Bruix¹, Morris Sherman; American Association for the Study of Liver Diseases

Affiliation

¹ Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain. bruix@ub.edu

PMID: 21374666
PMCID: PMC3084991
DOI: 10.1002/hep.24199

No abstract available

PubMed Disclaimer

Figures

Fig. 1 — Fig. 1
Diagnostic algorithm for suspected HCC. CT, computed tomography; MDCT, multidetector CT; MRI, magnetic resonance imaging; US, ultrasound.

Fig. 2 — Fig. 2
The BCLC staging system for HCC. M, metastasis classification; N, node classification; PS, performance status; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.

See this image and copyright information in PMC

Comment in

Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases.
Marrero JA, El-Serag HB. Marrero JA, et al. Hepatology. 2011 Mar;53(3):1060-1; author reply 1061-2. doi: 10.1002/hep.24033. Epub 2010 Dec 28. Hepatology. 2011. PMID: 21374678 No abstract available.
Updated management of hepatocellular carcinoma.
Lo GH. Lo GH. Hepatology. 2011 Sep 2;54(3):1113. doi: 10.1002/hep.24378. Epub 2011 Jul 21. Hepatology. 2011. PMID: 21520202 No abstract available.
Postoperative transcatheter arterial chemoembolization should be recommended in the hepatocellular carcinoma treatment guidelines of the American Association for the Study of Liver Diseases.
Wang Z, Li Z, Ji Y. Wang Z, et al. Hepatology. 2011 Oct;54(4):1489-90. doi: 10.1002/hep.24446. Epub 2011 Jul 21. Hepatology. 2011. PMID: 21618569 No abstract available.

Similar articles

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E. Sinakos E, et al. Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335. Scand J Gastroenterol. 2010. PMID: 20113152 No abstract available.
Major achievements in hepatocellular carcinoma.
Bruix J, Llovet JM. Bruix J, et al. Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. Lancet. 2009. PMID: 19231618 No abstract available.
Contemporary management of hepatocellular carcinoma.
Palmer D. Palmer D. Clin Med (Lond). 2008 Aug;8(4):442-7. doi: 10.7861/clinmedicine.8-4-442. Clin Med (Lond). 2008. PMID: 18724617 Free PMC article. Review. No abstract available.
Current management of hepatocellular carcinoma.
Mendizabal M, Reddy KR. Mendizabal M, et al. Med Clin North Am. 2009 Jul;93(4):885-900, viii. doi: 10.1016/j.mcna.2009.03.004. Med Clin North Am. 2009. PMID: 19577120 Review.
TACE with or without systemic therapy?
Dufour JF. Dufour JF. J Hepatol. 2012 Jun;56(6):1224-5. doi: 10.1016/j.jhep.2012.02.011. Epub 2012 Mar 5. J Hepatol. 2012. PMID: 22402292 No abstract available.

See all similar articles

Cited by

Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study.
Watanabe Y, Aikawa M, Kato T, Takase K, Watanabe Y, Okada K, Okamoto K, Koyama I. Watanabe Y, et al. Surg Endosc. 2023 Feb;37(2):1316-1333. doi: 10.1007/s00464-022-09677-x. Epub 2022 Oct 6. Surg Endosc. 2023. PMID: 36203111 Free PMC article.
Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma.
El-Abd N, Fawzy A, Elbaz T, Hamdy S. El-Abd N, et al. Tumour Biol. 2016 Jan;37(1):211-6. doi: 10.1007/s13277-015-3524-x. Epub 2015 Jul 20. Tumour Biol. 2016. PMID: 26189841
Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients.
Chen CZ, Zhong JH, Qi YP, Zhang J, Huang T, Ma L, Li LQ, Peng T, Xiang BD. Chen CZ, et al. Biosci Rep. 2021 Apr 30;41(4):BSR20201928. doi: 10.1042/BSR20201928. Biosci Rep. 2021. PMID: 33835138 Free PMC article.
Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis.
Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, Ijzermans JN. Witjes CD, et al. Hepatol Int. 2013 Mar;7(1):59-64. doi: 10.1007/s12072-012-9374-3. Epub 2012 May 12. Hepatol Int. 2013. PMID: 23519638 Free PMC article.
Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma.
Jin H, Wang H, Li G, Hou Q, Wu W, Liu F. Jin H, et al. J Int Med Res. 2020 Oct;48(10):300060520961260. doi: 10.1177/0300060520961260. J Int Med Res. 2020. PMID: 33044114 Free PMC article.

See all "Cited by" articles

References

1. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–88. - PubMed
1. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28:2437–2444. - PubMed
1. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148. - PMC - PubMed
1. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology. 2008;48:863–870. - PubMed
1. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information